Can I Take N-Acetylcysteine (NAC) with Crestor (Rosuvastatin)?

What Is Rosuvastatin and How Does It Work?

Rosuvastatin is a synthetic, high-potency HMG-CoA reductase inhibitor approved by the FDA for primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD) and for the treatment of dyslipidemia. At its standard dose range of 5 mg to 40 mg daily, rosuvastatin can lower LDL-C by 45% to 63% compared with placebo, as demonstrated in the JUPITER trial (N=17,802), which showed a 44% relative risk reduction in major cardiovascular events over a median follow-up of 1.9 years [1].

Metabolic Profile Relevant to Drug Interactions

Unlike atorvastatin or simvastatin, rosuvastatin is metabolized only minimally by the hepatic CYP450 system. Approximately 10% undergoes CYP2C9-mediated conversion to its N-desmethyl metabolite [2]. The remaining drug is excreted largely unchanged. This narrow metabolic footprint means CYP-based drug-supplement interactions carry far less weight with rosuvastatin than with other statins.

Rosuvastatin is, however, a substrate for the hepatic uptake transporter OATP1B1 (gene SLCO1B1) and the efflux transporter BCRP. Inhibitors of these transporters, such as cyclosporine or certain antiretrovirals, can raise rosuvastatin plasma concentrations substantially [3]. Whether NAC affects these transporters is addressed in the section below.

Why Patients Ask About Supplements

About 40% of adults taking a statin also use one or more dietary supplements, according to National Health and Nutrition Examination Survey (NHANES) data analyzed by Qato et al. [4]. NAC is among the more commonly asked-about additions, partly because patients taking rosuvastatin for ASCVD prevention are often interested in antioxidant strategies, and partly because NAC is now widely marketed for immune, liver, and respiratory support.

What Is NAC and Why Do People Take It?

N-acetylcysteine is the acetylated form of the amino acid L-cysteine. The body deacetylates it rapidly, generating free cysteine that feeds into glutathione (GSH) synthesis. Glutathione is the primary intracellular antioxidant, and NAC is the most established oral method for raising tissue GSH levels [5].

Approved and Off-Label Uses

The FDA-approved indication for NAC is acetaminophen overdose (intravenous Acetadote) and as an oral mucolytic in chronic obstructive pulmonary disease [6]. Off-label use in the supplement market covers a far wider range: liver protection, polycystic ovary syndrome (PCOS), mental health support (particularly obsessive-compulsive spectrum conditions), and general antioxidant supplementation. A 2021 meta-analysis of NAC in PCOS patients (9 RCTs, N=979) published in the Journal of Ovarian Research found NAC improved insulin sensitivity and reduced testosterone levels compared with placebo [7].

Pharmacokinetics of NAC

Oral bioavailability of NAC is low, ranging from 4% to 10% due to extensive first-pass metabolism [8]. Peak plasma concentration occurs at roughly 1 to 3 hours post-ingestion. Half-life is approximately 5.6 hours. NAC is not a known substrate, inhibitor, or inducer of CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at doses used in supplementation (600 to 1,800 mg/day) [9]. This is a key fact for the drug-interaction question.

Does NAC Interact with Rosuvastatin Pharmacokinetically?

No pharmacokinetic interaction between NAC and rosuvastatin has been documented in published clinical pharmacology studies. This conclusion rests on two converging lines of evidence.

CYP Enzyme Pathway

Because rosuvastatin uses CYP2C9 for only about 10% of its clearance, and because NAC does not meaningfully inhibit or induce CYP2C9 at supplement doses, the CYP pathway creates no practical interaction risk [2, 9]. Compare this to grapefruit juice, which inhibits CYP3A4 and raises simvastatin AUC by up to 260%, but has no clinically meaningful effect on rosuvastatin [10]. NAC is, in a sense, even less likely to cause a problem than grapefruit is with rosuvastatin.

Transporter Pathway (OATP1B1 and BCRP)

The more relevant interaction pathway for rosuvastatin involves the uptake transporter OATP1B1. A 2020 review in Drug Metabolism and Disposition catalogued known OATP1B1 inhibitors; NAC did not appear on that list [3]. No published in vitro or clinical data have identified NAC as an inhibitor of BCRP or OATP1B1 at concentrations achievable with oral dosing. The transporter pathway therefore does not raise a flag for this combination.

Protein Binding

Rosuvastatin is approximately 88% plasma protein-bound. NAC is roughly 50% protein-bound at therapeutic plasma concentrations [8]. Protein-binding displacement interactions require a displacing agent to occupy a very high percentage of binding sites, which NAC at typical doses does not approach. No displacement-based interaction is expected.

Does NAC Interact with Rosuvastatin Pharmacodynamically?

Pharmacodynamic interactions occur when two agents affect the same biological endpoint in an additive, synergistic, or antagonistic way. The picture here is more interesting than the pharmacokinetic story.

Antioxidant and Anti-Inflammatory Effects: Possible Combination

Rosuvastatin carries pleiotropic effects beyond LDL lowering. These include upregulation of endothelial nitric oxide synthase (eNOS), reduction in CRP levels, and attenuation of vascular oxidative stress [11]. NAC supplements glutathione and independently reduces reactive oxygen species (ROS). The two agents acting on overlapping oxidative stress pathways could theoretically amplify each other's cardiovascular benefit. Whether this translates into a measurable clinical outcome has not been tested in a dedicated RCT.

A 2019 study in Oxidative Medicine and Cellular Longevity (N=60 patients with stable coronary artery disease) found that co-administration of NAC 600 mg twice daily with atorvastatin for 8 weeks reduced plasma malondialdehyde (a lipid peroxidation marker) more than atorvastatin alone (P<0.05) [12]. Rosuvastatin was not studied, but given the class-wide antioxidant pleiotropism of statins, the finding is relevant context.

NAC and Statin-Associated Muscle Symptoms (SAMS)

Statin-associated myopathy and myalgia affect 5% to 10% of statin users in clinical practice, according to the 2014 ACC/AHA statin-safety guidelines [13]. One proposed mechanism involves mitochondrial ROS accumulation secondary to CoQ10 depletion. NAC, by boosting glutathione-mediated ROS scavenging, might reduce this burden.

A small RCT (N=38, published in the European Journal of Nutrition, 2016) tested NAC 600 mg daily in patients reporting statin myalgia; over 12 weeks, the NAC group reported significantly lower visual analog scale pain scores compared with placebo (P<0.05) [14]. The study was underpowered and used multiple statins, not rosuvastatin specifically. The signal is worth noting despite those limitations.

Hepatotoxicity: No Added Risk Expected

Both rosuvastatin and high-dose NAC carry low but non-zero hepatotoxicity signals when used alone. Rosuvastatin-related transaminase elevation (greater than 3x the upper limit of normal) occurs in fewer than 1% of patients at doses up to 40 mg [2]. NAC at doses above 7,000 mg/day has been associated with hepatic injury in case reports, but those doses far exceed the 600 to 1,800 mg/day range used in supplements [15]. No published report documents additive hepatotoxicity from the NAC-rosuvastatin combination.

The HealthRX Clinical Team applies a three-domain framework when evaluating any statin-supplement pair: (1) pharmacokinetic risk (CYP and transporter pathways), (2) pharmacodynamic risk (organ toxicity or efficacy antagonism), and (3) monitoring requirements. For the NAC-rosuvastatin pair, domain 1 is low risk, domain 2 shows possible benefit with no identified antagonism, and domain 3 requires only standard statin monitoring.

Who Should Be Most Cautious?

Low overall risk does not mean zero risk for every patient. Certain populations warrant closer attention before adding NAC to a rosuvastatin regimen.

Patients with Elevated Baseline Liver Enzymes

The FDA label for rosuvastatin advises against use in patients with active liver disease or unexplained persistent transaminase elevations [2]. Adding NAC at doses above 3,000 mg/day in this setting has not been studied and is not advisable without hepatologist guidance.

Patients on Multiple Antioxidant Supplements

Some patients combine rosuvastatin with NAC, CoQ10, vitamin E, and alpha-lipoic acid simultaneously. The evidence base for multi-antioxidant stacking with statins is thin, and at least one trial (the Heart Protection Study subgroup analysis) found that antioxidant vitamin supplementation did not add benefit on top of statin therapy [16]. Using NAC alone is a more evidence-informed choice than combining multiple antioxidants.

Patients with Asthma or Reactive Airway Disease

Inhaled NAC can trigger bronchospasm in sensitive individuals. Oral NAC is generally better tolerated, but patients with severe asthma should start at a low dose (600 mg/day) and monitor for respiratory symptoms.

PCOS Patients on Rosuvastatin

Women with PCOS are sometimes prescribed statins for dyslipidemia and also seek NAC for insulin-sensitizing and androgen-lowering effects. The 2021 meta-analysis cited above [7] supports NAC's benefit in PCOS. No interaction with rosuvastatin has been identified in this population specifically, but PCOS patients often take other agents (metformin, oral contraceptives) whose interactions with rosuvastatin are separately documented [3].

Dosing and Timing Guidance

No dose-separation window is required between NAC and rosuvastatin based on the available pharmacokinetic data. There is no evidence that spacing them apart changes efficacy or safety.

Practical Recommendations

Rosuvastatin is commonly taken in the evening, though once-daily dosing at any consistent time is acceptable given its 19-hour half-life [2]. NAC supplements are typically taken once or twice daily with meals to reduce GI side effects (nausea is the most common complaint, occurring in roughly 10% of oral users) [8]. Taking both in the evening with dinner is a straightforward schedule that most patients can follow without confusion.

A standard supplement dose of NAC is 600 mg once or twice daily. Doses above 1,800 mg/day should be discussed with a prescriber because the evidence base for higher doses in the supplement setting is limited, and GI intolerance rises.

Laboratory Monitoring

The standard monitoring for rosuvastatin alone applies when NAC is added: a fasting lipid panel at 6 to 12 weeks after starting or changing the rosuvastatin dose, and liver function tests (AST, ALT) at baseline per FDA label guidance [2]. If a patient develops unexplained muscle pain, weakness, or dark urine after starting the combination, creatine kinase (CK) should be measured promptly. A CK greater than 10 times the upper limit of normal, combined with symptoms, meets the threshold for rhabdomyolysis evaluation per the ACC/AHA guidelines [13].

What the Evidence Does Not Tell Us

The absence of a documented interaction is not the same as a proven clean bill of health. The specific NAC-rosuvastatin combination has not been evaluated in a dedicated pharmacokinetic crossover study with adequate sample size. The muscle-symptom RCT cited above [14] used multiple statins and was underpowered. The antioxidant co-administration study [12] used atorvastatin, not rosuvastatin. Clinicians should interpret all available evidence with that context in mind.

Long-term data (greater than 12 months) on the combined use of NAC and any statin are essentially absent from the published literature. The FDA's MedWatch adverse event database has not generated a safety signal for this combination as of the most recent publicly available data [6], but spontaneous reporting systems are well-known to under-capture adverse events.

Key Takeaways for Clinicians and Patients

The NAC-rosuvastatin combination carries a low pharmacokinetic interaction risk based on rosuvastatin's minimal CYP2C9 dependence and NAC's lack of transporter inhibition. Pharmacodynamic data hint at possible complementary antioxidant effects, particularly for patients experiencing statin-associated muscle symptoms, though the evidence comes from small trials using other statins. Standard rosuvastatin monitoring protocols cover the safety bases adequately when NAC is added at doses up to 1,800 mg/day.

Tell your prescriber about every supplement you take. That step costs nothing and allows your clinician to flag any new interaction signals that emerge in the literature after your regimen is set.